Concert Pharmaceuticals Garners $37,000,000 Series C Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=99d7c5fd-86fd-429f-8441-833564ee286a&Preview=1 -
Date
4/30/2008 -
Company Name
Concert Pharmaceuticals -
Mailing Address
99 Hayden Avenue Lexington, MA 02421 -
Company Description
Concert Pharmaceuticals, a privately held pharmaceutical company, is focused on developing novel small molecule drugs for unmet medical needs. Concert utilizes its advanced methodology to rapidly create potent bioavailable drug candidates. -
Website
http://www.concertpharma.com/
-
Transaction Type
Venture Equity -
Transaction Amount
$37,000,000 -
Transaction Round
Series C -
Proceeds Purposes
The Company intends to use the proceeds to further advance its deuterium chemistry platform and product pipeline. -
M&A Terms
-
Venture Investor
Undisclosed -
Venture Investor
Adage Capital Management -
Venture Investor
Three Arch Partners -
Venture Investor
TVM Capital -
Venture Investor
Skyline Ventures -
Venture Investor
Flagship Ventures -
Venture Investor
Brookside Capital -
Venture Investor
Greylock Partners -
Venture Investor
New Leaf Venture Partners -
Venture Investor
QVT Fund LP
